...the prior period. The company dealt with the impact of volume-based procurement on joint replacement implants and COVID lockdowns in its domestic Chinese market. MicroPort’s international markets performed well, particularly...
...the APAC region remains disrupted due to COVID, Brazil was a standout performer in the ROW category. LimaCorporate expects to sustain growth through the rest of the year across its...
...international markets created a choppy end to the first half. Orthopedic Procedure Volumes Constrained by Hospital Staffing Shortage Several orthopedic companies reported baseline procedure volumes at pre-COVID levels. However, hospital...
...in the EMEA region. However, COVID lockdowns severely impacted the company’s largest APAC markets of Australia and New Zealand. Medartis also plans to discontinue sales in China as volume-based procurement...
Medacta reported 1H22 orthopedic sales of $215.5 million, +19% compared to the first half of 2021. Continued salesforce expansion, new customer acquisition and new product introductions drove Medacta’s growth. COVID...
Paragon 28 reported 2Q22 orthopedic sales of $42.5 million, +18.9% compared to 2Q21. The company experienced modest COVID disruptions to procedure volume, but offset those via increased revenue contributions from...
Zimmer Biomet reported 2Q22 orthopedic sales of $1.8 billion, +1% vs. 2Q21. The company exceeded its internal expectations for the quarter, citing COVID recovery and execution across the company’s regions...
...fraught with disruption. Volume-based purchasing in China had a negative $20 million impact for Smith+Nephew in the second quarter, and COVID lockdowns there hurt demand for sports medicine. The company...
...company faced a steep comparison going against 2Q21, its second-highest total revenue quarter in the last three and a half years. COVID restrictions, particularly in China, also hurt DePuy Synthes’...
...both fiscal and clinical sense for both companies. Spine has a lot of players. It’s recovering from COVID. How would you describe today’s spine market? Mr. Roof: I think it’s...
